Imiquimod: Unexpected Killer
نویسندگان
چکیده
منابع مشابه
Imiquimod.
The imidazoquinoline, imiquimod, is a low molecular weight, synthetic immune response modifier that is used for the treatment of external genital and perianal warts. It is formulated in a 5% vanishing cream as Aldara. This self-applied therapy has shown good efficacy and safety in the treatment of external genital and perianal warts caused by human papillomavirus (HPV) infection. The antiviral ...
متن کامل[Photodynamic therapy vs imiquimod].
Photodynamic therapy and imiquimod are highly regarded treatments dermatologists frequently prescribe for actinic keratoses, basal cell carcinoma, and Bowen disease. The scarcity of evidence from comparative trials prevents us from drawing well-founded conclusions about the efficacy, tolerance, and adverse effects of these therapeutic options or to recommend one over the other in any particular...
متن کاملImiquimod (Aldara cream).
IMIQUIMOD CREAM: INDICATION Imiquimod (AldaraTM, 3M Pharmaceuticals, St. Paul, MN) is an immune-response modifier. In the United States, it is currently indicated for the treatment of external anogenital warts. Available in a 5% cream, it is applied by the patient to the warts and adjacent skin three times a week (e.g., Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday) for up to...
متن کاملThe unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations.
Cyclosporin A (CSA) is commonly used to prevent graft-versus-host disease. The influence of CSA on T-cell function has been extensively investigated; however, the effect of CSA on natural killer (NK) cells is less understood. NK cells were cultured with IL-2 and IL-15 with and without CSA for 1 week. Compared with controls, CSA-treated cultures showed fewer CD56(+)CD16(+)KIR(+) NK cells and a r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Investigative Dermatology
سال: 2004
ISSN: 0022-202X
DOI: 10.1111/j.0022-202x.2004.22537.x